Mrs Julie Ann Trimarco Price, | |
1045 Maryland Ave, Hagerstown, MD 21740-7201 | |
(301) 739-5437 | |
(301) 739-7453 |
Full Name | Mrs Julie Ann Trimarco Price |
---|---|
Gender | Female |
Speciality | Speech-language Pathologist |
Location | 1045 Maryland Ave, Hagerstown, Maryland |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1205250222 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
235Z00000X | Speech-language Pathologist | 09339 (Maryland) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Julie Ann Trimarco Price, 1045 Maryland Ave, Hagerstown, MD 21740-7201 Ph: (412) 925-3504 | Mrs Julie Ann Trimarco Price, 1045 Maryland Ave, Hagerstown, MD 21740-7201 Ph: (301) 739-5437 |
News Archive
Health advocates and some lawmakers rallied last week in Tallahassee to expand Medicaid coverage, but the Florida House speaker says the expansion is "dead" in his state. In addition, debate over this health law provision continues in Louisiana.
Engineers from Michigan State University have secured $3.4 million in grants to develop diamond implants that could let doctors diagnose and treat Parkinson's disease earlier.
Beginning in 2014, Springer will publish the Journal of Nephrology, the official publication of the Italian Society of Nephrology. The new agreement will enable the journal to expand and strengthen its mission to stimulate advancements in medicine, focusing on nephrology, dialysis and renal transplantation.
The ongoing meningitis outbreak and its impact on patients and their families is a tragedy, and our hearts go out to the patients and their families who have suffered as a result of these events. The FDA's top priority is to fully contain the health risks associated with the outbreak as quickly as possible, and we will continue to work tirelessly to do so.
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE(bortezomib), which updates the label to include the subcutaneous method of administration in all approved indications: multiple myeloma and mantle cell lymphoma after at least one prior therapy.
› Verified 4 days ago
Lindsay Daugherty, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 10435 Downsville Pike, Hagerstown, MD 21740 Phone: 301-766-8313 | |
Mrs. Brittany Michael, MSCCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 10435 Downsville Pike, Hagerstown, MD 21740 Phone: 301-766-2800 | |
Marybeth Raidt, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 10435 Downsville Pike, Hagerstown, MD 21740 Phone: 301-766-8282 | |
Danielle Mullendore, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 10435 Downsville Pike, Hagerstown, MD 21740 Phone: 301-766-2800 | |
Christina Rapp, MS CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 10435 Downsville Pike, Hagerstown, MD 21740 Phone: 301-766-2800 | |
Rachel Lee Gurecki, MS,SLP,CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 11110 Medical Campus Rd, 201, Hagerstown, MD 21742 Phone: 301-714-4025 Fax: 301-714-4026 | |
Kymberli Dixon, SPEECH THERAPY Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 11110 Medical Campus Rd, 201, Hagerstown, MD 21742 Phone: 301-714-4025 Fax: 301-714-4026 |